Clinical trials for cancer patients
The Clínica is the private center that promotes the most clinical trials in Spain. We aim to generate knowledge to change the course of diseases.
-
September 21, 2026PamplonaIn recruitmentEarly phase
2015-0001 “Clinical trial investigating how well different doses of BI 3822971 are tolerated by people with advanced cancer (solid tumors)”
This study is open to adults with advanced or metastatic solid tumors, such as non-small cell lung cancer, head and neck squamous cell carcinoma, triple-negative breast cancer, esophageal squamous cell carcinoma, bladder cancer, vulvar cancer, and cervical cancer. Patients may participate if no standard treatment options are available to them and they have a measurable lesion outside the central nervous system. The aim of this study is to determine how well BI 3822971 is tolerated by people with... -
September 21, 2026PamplonaIn recruitment
CA239-0071 Clinical trial for the long-term treatment of patients with cancer who have participated in BMS parent studies investigating adagrasib (BMS-986503).
This study is designed to collect long-term safety data and provide uninterrupted study treatment to participants with solid tumors who continue to benefit from adagrasib in an eligible clinical trial (parent study). -
September 16, 2026PamplonaIn recruitmentEarly phase
68284528MMY2012 Phase 2, multicohort clinical trial to further characterize the efficacy and safety of ciltacabtagene autoleucel
The aim of this study is to gather further information on how cilta-cel works and its safety in the treatment of patients with multiple myeloma, a type of cancer. The study will include different groups of patients, referred to as cohorts. -
September 15, 2026Pamplona/MadridIn recruitment
CA266-0006 Phase 1/2, open-label, multicenter, randomized clinical trial of pumitamig alone or in combination with ipilimumab in participants with advanced or unresectable hepatocellular carcinoma (HCC) in the first-line setting
This study is designed to help determine whether the study drug pumitamig is effective in treating hepatocellular carcinoma (HCC), a type of liver cancer that is advanced or cannot be removed by surgery (referred to as unresectable). -
September 15, 2026Pamplona/MadridIn recruitment
M26-092 Clinical trial evaluating the safety and efficacy of pivekimab sunirine (PVEK) in combination with venetoclax and azacitidine in adult participants with newly diagnosed acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy
The aim of this study is to determine the safety and efficacy (how well the study drugs work) of PVEK in combination with venetoclax (VEN) and azacitidine (AZA) in adult patients with newly diagnosed acute myeloid leukemia (AML) who are unable to receive intensive chemotherapy. -
September 8, 2026PamplonaIn recruitmentEarly phase
3082-CL-0101 Phase I clinical trial of ASP3082 in participants with locally advanced or metastatic solid malignancies harboring a KRAS G12D mutation.
The objective of this study is to determine whether combination therapies with the study drugs—that is, ASP3082 and docetaxel, pembrolizumab, or a platinum-based chemotherapy regimen (cisplatin or carboplatin) and pemetrexed, with or without pembrolizumab—are safe and effective for treating people with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring a KRAS G12D mutation. -
September 3, 2026Pamplona/MadridIn recruitmentEarly phase
CTL-002-005 Clinical trial investigating the efficacy and safety of visugromab in combination with nivolumab and lenvatinib compared with double placebo and lenvatinib in participants with unresectable or metastatic hepatocellular carcinoma and compensated liver function (Child-Pugh Class A) following failure of first-line treatment that included an anti-PD-(L)1 agent.
The objective of this trial is to determine how well a new investigational drug called visugromab (also known as CTL-002) works and whether it is safe when used in combination with nivolumab and lenvatinib. -
August 27, 2026Pamplona/MadridIn recruitmentEarly phase
XmAb541-01 Phase 1 clinical trial to evaluate XmAb541 in advanced solid tumors.
The primary objective is to evaluate the safety and tolerability of the study drug. -
August 26, 2026Pamplona/MadridIn recruitment
PEAK-1 Clinical trial to evaluate casdatifan and cabozantinib compared with placebo and cabozantinib in patients with advanced clear cell renal cell carcinoma.
The purpose of the study is to evaluate progression-free survival (PFS) with casdatifan versus placebo, when both are administered in combination with cabozantinib, in adult patients with confirmed advanced or metastatic clear cell renal cell carcinoma who experienced disease progression during or after prior anti-PD-1 or anti-PD-L1 immunotherapy. -
August 26, 2026Pamplona/MadridIn recruitment
3138001 "Phase I/II, open-label clinical trial evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of ODM-216 in participants with advanced solid tumors."
This is the first time ODM-216 is being tested in humans. ODM-216 is a type of immunotherapy. It works by helping the immune system better recognize and respond to cancer. The primary objective of this study is to determine the safety and tolerability of ODM-216 and establish the optimal dose.